Fractyl Health’s (GUTS) Buy Rating Reaffirmed at HC Wainwright

Fractyl Health (NASDAQ:GUTS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $8.00 price target on the stock.

Several other research analysts have also weighed in on GUTS. Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $8.00 to $2.00 in a research report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research note on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Trading Down 1.6%

Shares of Fractyl Health stock opened at $0.58 on Friday. The firm has a market capitalization of $92.18 million, a price-to-earnings ratio of -0.32 and a beta of 1.20. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $3.03. The company has a debt-to-equity ratio of 3.23, a quick ratio of 4.78 and a current ratio of 4.78. The stock has a 50 day moving average of $0.48 and a 200 day moving average of $1.19.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.34. As a group, research analysts predict that Fractyl Health will post -0.67 earnings per share for the current year.

Institutional Trading of Fractyl Health

Several hedge funds have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in shares of Fractyl Health by 23.5% in the third quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock valued at $141,000 after acquiring an additional 16,856 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Fractyl Health in the second quarter valued at $31,000. FNY Investment Advisers LLC acquired a new stake in shares of Fractyl Health in the third quarter valued at $31,000. Jump Financial LLC acquired a new stake in shares of Fractyl Health in the fourth quarter valued at $57,000. Finally, Scientech Research LLC acquired a new stake in shares of Fractyl Health in the third quarter valued at $49,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.